BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo J, Yu FX. GPCR-Hippo Signaling in Cancer. Cells 2019;8:E426. [PMID: 31072060 DOI: 10.3390/cells8050426] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Zheng M, Jacob J, Hung SH, Wang J. The Hippo Pathway in Cardiac Regeneration and Homeostasis: New Perspectives for Cell-Free Therapy in the Injured Heart. Biomolecules 2020;10:E1024. [PMID: 32664346 DOI: 10.3390/biom10071024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Rausch V, Hansen CG. The Hippo Pathway, YAP/TAZ, and the Plasma Membrane. Trends Cell Biol 2020;30:32-48. [PMID: 31806419 DOI: 10.1016/j.tcb.2019.10.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
3 Szulzewsky F, Holland EC, Vasioukhin V. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Dev Biol 2021;475:205-21. [PMID: 33428889 DOI: 10.1016/j.ydbio.2020.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhu L, Lu J, Bao Z, Guo S, Li W. Mechanism of Baclofen Inhibiting the Proliferation and Metastasis of GBM by Regulating YAP. Journal of Chemistry 2021;2021:1-10. [DOI: 10.1155/2021/2753571] [Reference Citation Analysis]
5 Lo EKK, Lee JC, Turner PC, El-Nezami H. Low dose of zearalenone elevated colon cancer cell growth through G protein-coupled estrogenic receptor. Sci Rep 2021;11:7403. [PMID: 33795755 DOI: 10.1038/s41598-021-86788-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Wang M, Dai M, Wang D, Tang T, Xiong F, Xiang B, Zhou M, Li X, Li Y, Xiong W, Li G, Zeng Z, Guo C. The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway. Cancer Lett 2021;512:60-72. [PMID: 33951538 DOI: 10.1016/j.canlet.2021.04.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Gu Y, Wang Y, Wang Y, Luo J, Wang X, Ma M, Hua W, Liu Y, Yu FX. Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas. Front Cell Dev Biol 2020;8:586581. [PMID: 33195240 DOI: 10.3389/fcell.2020.586581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Soond SM, Zamyatnin AA Jr. Targeting G protein-coupled receptors in cancer therapy. Adv Cancer Res 2020;145:49-97. [PMID: 32089165 DOI: 10.1016/bs.acr.2019.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lo Iacono M, Signorino E, Petiti J, Pradotto M, Calabrese C, Panuzzo C, Caciolli F, Pergolizzi B, De Gobbi M, Rege-Cambrin G, Fava C, Giachino C, Bracco E, Saglio G, Frassoni F, Cilloni D. Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1. Cancers (Basel) 2021;13:293. [PMID: 33466839 DOI: 10.3390/cancers13020293] [Reference Citation Analysis]
10 Swaroop B SS, Kanumuri R, Ezhil I, Naidu Sampangi JK, Kremerskothen J, Rayala SK, Venkatraman G. KIBRA connects Hippo signaling and cancer. Exp Cell Res 2021;403:112613. [PMID: 33901448 DOI: 10.1016/j.yexcr.2021.112613] [Reference Citation Analysis]
11 Yin X, Yin Y, Dai L, Shen C, Chen N, Li J, Cai Z, Jiang Z, Wang J, Zhao Z, Chen X, Deng H, Zhang B. Integrated analysis of long non-coding RNAs and mRNAs associated with malignant transformation of gastrointestinal stromal tumors. Cell Death Dis 2021;12:669. [PMID: 34218261 DOI: 10.1038/s41419-021-03942-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Zhang A, Wang W, Chen Z, Pang D, Zhou X, Lu K, Hou J, Wang S, Gao C, Lv B, Yan Z, Chen Z, Zhu J, Wang L, Zhuang T, Li X. SHARPIN Inhibits Esophageal Squamous Cell Carcinoma Progression by Modulating Hippo Signaling. Neoplasia 2020;22:76-85. [PMID: 31884247 DOI: 10.1016/j.neo.2019.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang G, Li HN, Cui XQ, Xu T, Dong ML, Li SY, Li XR. S100A1 is a Potential Biomarker for Papillary Thyroid Carcinoma Diagnosis and Prognosis. J Cancer 2021;12:5760-71. [PMID: 34475990 DOI: 10.7150/jca.51855] [Reference Citation Analysis]
14 Hansen CG. Special Issue on "Disease and the Hippo Pathway". Cells 2019;8:E1179. [PMID: 31575050 DOI: 10.3390/cells8101179] [Reference Citation Analysis]
15 Zindel D, Mensat P, Vol C, Homayed Z, Charrier-Savournin F, Trinquet E, Banères JL, Pin JP, Pannequin J, Roux T, Dupuis E, Prézeau L. G protein-coupled receptors can control the Hippo/YAP pathway through Gq signaling. FASEB J 2021;35:e21668. [PMID: 34114695 DOI: 10.1096/fj.202002159R] [Reference Citation Analysis]
16 Lodrini AM, Goumans MJ. Cardiomyocytes Cellular Phenotypes After Myocardial Infarction. Front Cardiovasc Med 2021;8:750510. [PMID: 34820429 DOI: 10.3389/fcvm.2021.750510] [Reference Citation Analysis]
17 Morice S, Danieau G, Tesfaye R, Mullard M, Brion R, Dupuy M, Ory B, Brounais-Le Royer B, Corre I, Redini F, Verrecchia F. Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung Metastasis. Front Oncol 2021;11:765711. [PMID: 34765560 DOI: 10.3389/fonc.2021.765711] [Reference Citation Analysis]
18 Li L, Ugalde AP, Scheele CLGJ, Dieter SM, Nagel R, Ma J, Pataskar A, Korkmaz G, Elkon R, Chien MP, You L, Su PR, Bleijerveld OB, Altelaar M, Momchev L, Manber Z, Han R, van Breugel PC, Lopes R, Ten Dijke P, van Rheenen J, Agami R. A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis. Genome Biol 2021;22:54. [PMID: 33514403 DOI: 10.1186/s13059-021-02272-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Kovar H, Bierbaumer L, Radic-Sarikas B. The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. Cells 2020;9:E972. [PMID: 32326412 DOI: 10.3390/cells9040972] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
20 Park J, Hansen CG. Cellular feedback dynamics and multilevel regulation driven by the hippo pathway. Biochem Soc Trans 2021:BST20200253. [PMID: 34374419 DOI: 10.1042/BST20200253] [Reference Citation Analysis]
21 Lin YH, Lin YC, Chen CC. Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials. Cells 2021;10:1629. [PMID: 34209775 DOI: 10.3390/cells10071629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang H, Zhang H, Sun Z, Chen W, Miao C. GABAB receptor inhibits tumor progression and epithelial-mesenchymal transition via the regulation of Hippo/YAP1 pathway in colorectal cancer. Int J Biol Sci 2021;17:1953-62. [PMID: 34131398 DOI: 10.7150/ijbs.58135] [Reference Citation Analysis]
23 Sahu MR, Mondal AC. The emerging role of Hippo signaling in neurodegeneration. J Neurosci Res 2020;98:796-814. [PMID: 31705587 DOI: 10.1002/jnr.24551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
24 Tocci P, Blandino G, Bagnato A. YAP and endothelin-1 signaling: an emerging alliance in cancer. J Exp Clin Cancer Res 2021;40:27. [PMID: 33422090 DOI: 10.1186/s13046-021-01827-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D, Gutkind JS, Maggiolini M. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. Cells 2020;9:E1010. [PMID: 32325700 DOI: 10.3390/cells9041010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]